Social Media Ideas for Ocrevus

Latest updates for Ocrevus

Fresh curated links around Ocrevus are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Post angles to try

Share the most useful takeaway for your audience.

Turn one article into a quick practical checklist.

Ask your audience how this shift affects their work.

Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

multiplesclerosisnewstoday.com /2 weeks ago

Large study shows how 2 MS treatments stack up in the real world

Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) are both highly effective at preventing relapses and disability worsening in people with relapsing-remitting multiple sclerosis (RRM...

Read source

biopharmadive.com /1 week ago

Novartis says MS pill succeeds in two large studies

Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.

Read source

multiple-sclerosis-research.org /2 weeks ago

Comparing anti-CD20 antibodies. Is ofatumumab the same as ocrelizuamb?

The answer to this is unlikely to occur from a proper clinical trial done by pharma as it would be dangerous if there is a difference and one seems better than the other. MSBase is...

Read source

multiple-sclerosis-research.org /1 month ago

Stopping treatment with an anti-relapse agent in progressive MS. What does it tell us?

Ocrelizumab is licenced for relapsing and active primary progressive MS (Lesions and relapses) in the EU…It is active because we know it works by stopping B cells from entering the...

Read source

multiplesclerosisnewstoday.com /1 week ago

Experimental MS drug bests approved therapy in cutting relapses in 2 trials

An experimental oral drug called remibrutinib outperformed the approved therapy Aubagio (teriflunomide) in reducing disease flare rates in two large, late-stage clinical trials inv...

Read source

multiple-sclerosis-research.org /1 month ago

Why are people switching to anti-CD20 ocrelizumab under the skin?

A cynical view is because of marketing but it is more cost effective to health services as can be seen here. Zanghì A, Di Filippo PS, Rutigliano C, Moretti MC, Avolio C, D’Amico E....

Read source

cafepharma.com /1 day ago

Blenrep

Blenrep Anonymous (not verified) Tue, 09/08/2026 - 15:50 field_thread_url https://cafepharma.com/boards/threads/blenrep.714532/ board na...

Read source

parkinsonsnewstoday.com /1 month ago

Ongentys (opicapone) for Parkinson’s disease

Ongentys (opicapone) is an oral therapy approved as an add-on to a combination of levodopa and carbidopa for reducing off episodes in people with Parkinson’s disease. Off episodes...

Read source

multiple-sclerosis-research.org /1 month ago

New remyelination drug…Will it make it

Yang Y, Bai B, Knutsen LJS, Hamlyn RJ, Cui QL, Antel J, Macklin W, Medicetty S, Trapp BD. A novel small molecule remyelination therapy for multiple sclerosis. NPJ Drug Discov. 2026...

Read source

multiple-sclerosis-research.org /3 weeks ago

HE SC DMTs

Following on from the post on subcutaneous ofatumumab and intravenous ocrelizumab we had a question. “Is the Subcut version of Tysabri as effective as the infusion based on the cur...

Read source

biopharmadive.com /5 days ago

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

Read source

multiplesclerosisnewstoday.com /1 month ago

FDA feedback supports new testing path for therapy in MS relapses

After receiving positive regulatory feedback from the U.S. Food and Drug Administration (FDA), Oculis is planning to expand clinical testing of its experimental therapy privosegtor...

Read source

hemophilianewstoday.com /2 weeks ago

Obizur (susoctocog alfa) for hemophilia

Obizur (susoctocog alfa) is a recombinant porcine (pig-derived) factor VIII concentrate approved for the on-demand treatment of bleeds in adults with acquired hemophilia A. The pos...

Read source

healio.com /3 weeks ago

Duvakitug shows improved outcomes in ulcerative colitis, Crohn’s

An investigational anti-TL1A monoclonal antibody achieved “clinically meaningful” outcomes compared with placebo in patients with inflammatory bowel disease, according to results o...

Read source

multiple-sclerosis-research.org /3 weeks ago

Nalizumab does not have the cost-benefit of others

Manzano CL, Sadek A, Cooper C, Tomlinson E, Wang H, Rice C, Tallantyre E, Rao-Middleton A, Whiting P, Thom H. Natalizumab and Tyruko (natalizumab biosimilar) for treating highly ac...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.